Outcomes in early-stage non-small-cell lung cancer (NSCLC) are infamously poor. In the ANITA trial of patients with stage IB–IIIA disease,¹ median overall survival for after surgical resection was 43·7 months. Use of adjuvant chemotherapy improved outcome but median overall survival was still only 65·7 months, and meta-analyses² of NSCLC adjuvant chemotherapy trials suggest a relative survival benefit of just 5% at 5 years.² When Heather Wakelee and colleagues designed the E1505 trial in 2007, the results of which are reported in The Lancet Oncology, there was a massive unmet need for better therapeutics.

中文翻译：

---

贝伐单抗辅助治疗非小细胞肺癌

早期非小细胞肺癌（NSCLC）的结果非常差。在针对IB–IIIA期患者的ANITA试验中，手术切除后的中位总生存期为¹个，为43·7个月。辅助化疗的使用改善了结局，但中位总生存期仍仅为65·7个月，NSCLC辅助化疗试验的荟萃分析²显示5年相对生存率仅为5％。²当Heather Wakelee及其同事在2007年设计E1505试验时，《柳叶刀肿瘤学》（The Lancet Oncology）报道了该试验的结果，迫切需要更好的疗法。